Psychedelic clinical trials (psilocybin, LSD, etc) with Dr. Paul Thielking

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined again by Dr. Paul Thielking.  Paul is a psychiatrist, palliative care physician, zen practitioner, and the chief scientific officer at Novamind. Paul joins the show to talk about psychedelic clinical trials.

(2:15) Introduction to the topic
(4:11) Cedar Clinical Research
(4:45) What is a clinical trial?
(10:42) The unique challenges of psychedelic clinical trials and regulating psychedelic-assisted psychotherapy
(15:09) Risk Evaluation and Mitigation Strategy (REMS)
(18:06) The therapy part of psychedelic-assisted therapy
(24:13) How important is integration support after psychedelic experience
(26:33) The resources required to do psychedelic-assisted therapy
(29:55) The challenges of training enough therapists to do psychedelic-assisted therapy
(36:11) Psychedelic medicine accessibility and scaleability
(39:25) Placebo-controlled double-blind psychedelic studies
(44:02) Handling and accounting for disappointment when a trial participant gets the placebo
(49:11) Investigator initiated studies
(52:28) Compassionate use and expanded access
(55:45) What types of psychedelics are being studied in clinical trials

Email us questions and feedback at psychfrontiers@novamind.ca
Learn more about our podcast at https://www.psychedelictherapyfrontiers.com/
Learn more about Novamind at https://www.novamind.ca/
Follow us on Instagram:
https://www.instagram.com/drstevethayer/
https://www.instagram.com/innerspacedoctor/
https://www.instagram.com/novamind_inc/

Disclaimer: The content of this podcast does not constitute medical advice or mental health treatment. Consult with a medical/mental health professional if you believe you are in need of mental health treatment.